Suppr超能文献

经尿道前列腺部或膀胱颈部的术前活检阳性不一定会排除原位膀胱替代。

Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution.

机构信息

Department of Urology, University Hospital of Bern, University of Bern , Bern , Switzerland.

Department of Cell and Molecular Biology, University of Medicine and Pharmacy , Tirgu Mures , Romania.

出版信息

J Urol. 2019 May;201(5):909-915. doi: 10.1097/JU.0000000000000034.

Abstract

PURPOSE

We investigated the influence of positive pre-cystectomy biopsies of the prostatic urethra in males and the bladder neck in females on urethral recurrence, cancer specific and overall survival, and functional outcomes after orthotopic bladder substitution.

MATERIALS AND METHODS

We retrospectively analyzed the records of 803 consecutive patients, including 703 males and 100 females, who underwent orthotopic bladder substitution as well as pre-cystectomy biopsy of the prostatic urethra in males and the bladder neck in females, at our institution between April 1986 and December 2017.

RESULTS

Pre-cystectomy biopsies were negative in 755 of the 803 patients (94%) (group 1) and positive in 48 (6%) (group 2). Biopsies in group 2 revealed carcinoma in situ in 35 of the 48 cases (73%), pTaG1/G2 in 5 (10%) and pTaG3/pT1G3 in 8 (17%). Median followup was 64 months (IQR 21-128). At a median followup of 56 months (IQR 18-127) urethral recurrence developed in 45 of the 803 patients (5.6%), including 30 of the 755 (4%) in group 1 and 15 of the 48 (31.3%) in group 2 (p <0.001). Only 10 of the 45 patients (22%) with urethral recurrence required salvage urethrectomy while locally conservative treatment was successful in 27 (60%). Of the remaining 8 patients 6 of 45 (13%) underwent synchronous palliative chemotherapy and 2 of 45 (4%) refused treatment. Multivariate regression analysis revealed a higher risk of urethral recurrence if patients had positive pre-cystectomy biopsies (group 2 HR 6.49, 95% CI 3.33-12.62, p <0.001) or received neoadjuvant or adjuvant chemotherapy (HR 3.05, 95% CI 1.66-5.59, p <0.001). Cancer specific and overall survival as well as functional outcomes were similar in the 2 groups.

CONCLUSIONS

Positive pre-cystectomy biopsies prior to orthotopic bladder substitution increased the urethral recurrence rate but did not lower cancer specific or overall survival. Most urethral recurrences were managed successfully by local treatment. Orthotopic bladder substitution is an option in highly selected patients with positive, noninvasive pre-cystectomy biopsies, provided that they undergo regular followup including urethral cytology.

摘要

目的

我们研究了男性前列腺尿道和女性膀胱颈部的阳性术前活检对原位膀胱癌患者行原位膀胱替代术后尿道复发、癌症特异性和总体生存率以及功能结局的影响。

材料和方法

我们回顾性分析了 1986 年 4 月至 2017 年 12 月期间在我院接受原位膀胱替代术以及男性前列腺尿道和女性膀胱颈部术前活检的 803 例连续患者的记录,包括 703 例男性和 100 例女性。

结果

803 例患者中 755 例(94%)(组 1)术前活检为阴性,48 例(6%)(组 2)为阳性。组 2 的活检显示 35 例(73%)为原位癌,5 例(10%)为 pTaG1/G2,8 例(17%)为 pTaG3/pT1G3。中位随访时间为 64 个月(IQR 21-128)。在中位随访 56 个月(IQR 18-127)时,803 例患者中有 45 例(5.6%)发生尿道复发,其中组 1的 30 例(4%)和组 2 的 15 例(31.3%)(p <0.001)。在 45 例尿道复发患者中,仅 10 例(22%)需要挽救性尿道切除术,而 27 例(60%)局部保守治疗成功。其余 8 例患者中,6 例(45 例的 13%)接受了同步姑息性化疗,2 例(45 例的 4%)拒绝治疗。多变量回归分析显示,术前活检阳性(组 2 HR 6.49,95%CI 3.33-12.62,p <0.001)或接受新辅助或辅助化疗(HR 3.05,95%CI 1.66-5.59,p <0.001)的患者尿道复发风险更高。两组的癌症特异性和总体生存率以及功能结局相似。

结论

原位膀胱癌患者行原位膀胱替代术前阳性的术前活检会增加尿道复发率,但不会降低癌症特异性或总体生存率。大多数尿道复发通过局部治疗成功管理。对于术前活检阳性但非浸润性的高度选择患者,在接受定期随访包括尿道细胞学检查的情况下,可以选择行原位膀胱替代术。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验